- Home
- EXAS vs LEGN Comparison
EXAS vs LEGN Comparison
Compare EXAS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- LEGN
- Stock Information
- Founded
- EXAS 1995
- LEGN 2014
- Country
- EXAS United States
- LEGN United States
- Employees
- EXAS N/A
- LEGN N/A
- Industry
- EXAS Medical Specialities
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- LEGN Health Care
- Exchange
- EXAS Nasdaq
- LEGN Nasdaq
- Market Cap
- EXAS 10.7B
- LEGN 5.4B
- IPO Year
- EXAS N/A
- LEGN 2020
- Fundamental
- Price
- EXAS $53.36
- LEGN $35.64
- Analyst Decision
- EXAS Strong Buy
- LEGN Strong Buy
- Analyst Count
- EXAS 20
- LEGN 13
- Target Price
- EXAS $70.16
- LEGN $75.17
- AVG Volume (30 Days)
- EXAS 2.8M
- LEGN 2.0M
- Earning Date
- EXAS 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- EXAS N/A
- LEGN N/A
- EPS Growth
- EXAS N/A
- LEGN N/A
- EPS
- EXAS N/A
- LEGN N/A
- Revenue
- EXAS $2,828,128,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EXAS $14.58
- LEGN $65.49
- Revenue Next Year
- EXAS $12.75
- LEGN $53.76
- P/E Ratio
- EXAS N/A
- LEGN N/A
- Revenue Growth
- EXAS 11.57
- LEGN 112.46
- 52 Week Low
- EXAS $39.97
- LEGN $27.34
- 52 Week High
- EXAS $72.83
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EXAS 49.61
- LEGN 57.79
- Support Level
- EXAS $52.60
- LEGN $32.42
- Resistance Level
- EXAS $55.09
- LEGN $36.91
- Average True Range (ATR)
- EXAS 2.09
- LEGN 1.42
- MACD
- EXAS -0.01
- LEGN 0.02
- Stochastic Oscillator
- EXAS 44.73
- LEGN 67.58
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.